Crystalys lands $205M to bring gout drug first marketed in Japan to the US...
A team that got a gout treatment approved is coming back together to develop a new medicine for the condition in the US and Europe. Crystalys Therapeutics, the San Diego biotech developing the oral...
View ArticleWhite House confirms Section 232 pharma investigation has resulted in 100%...
A White House official confirmed to Endpoints News that President Donald Trumpâs social media post which said he'd put 100% tariffs on some branded drugs is a result of the administration's five-month...
View ArticleWalmart takes on wellness
Last Thursday, I stopped by Walmartâs first ever wellness event in swanky Chelsea, Manhattan. Influencers and members of the press milled about, sipping on healthy smoothies, playing pickleball,...
View ArticleMFN updates: Trump drug price announcement on most favored nation
President Donald Trump said Tuesday that Pfizer has agreed to offer all new medicines at âmost favored nationâ prices, the first drugmaker to make a deal in line with the White Houseâs push to tie ...
View ArticleBarinthusâ reverse merger with private biotech; Sutro to lay off 33% of...
Plus, news about Ocular Therapeutix, Kardigan, ARS Pharmaceuticals, Full-Life Technologies, Orion, Novo Nordisk, Nxera Pharma and UniQure: đ Barinthus Biotherapeutics inks reverse merger: The UK...
View ArticleMerck makes the case for PAH drug Winrevair in patients with earlier disease
Merck's pulmonary arterial hypertension drug Winrevair cut the risk of âclinical worseningâ â an endpoint made up of a variety of signs showing that a patient's illness is progressing â by 76% in...
View ArticleUnder new CEO, Novo ends heart failure partnership with Japanese biotech
A small Japanese biotech said it was blindsided by Novo Nordiskâs decision to terminate their work developing a stem cell-based therapy for heart failure. The Danish drug giant ended the collaboration,...
View ArticleâLikelyâ government shutdown threatens to stress an already depleted FDA
Absent an agreement before midnight, the federal government is headed for a shutdown on Wednesday, potentially leading to tens of thousands of furloughs at HHS and further complicating the work of a...
View ArticleFDA approves Novartis' BTK inhibitor for chronic hives
The FDA on Tuesday approved Novartis' BTK inhibitor to treat patients with chronic spontaneous urticaria, also known as chronic hives. The drug, remibrutinib, will be branded as Rhapsido. Itâs the...
View ArticleWhat we do and donât know after the White Houseâs deal with Pfizer
The White House heralded its new drug pricing agreement with Pfizer, saying it was prioritizing fairness for American consumers and that it would be the first of many deals struck with drug...
View ArticleAfter building Ochre Bio, Jack O'Meara's newest biotech raises $21M for neuro...
A biotech in Dublin and London wants to jump into the bustling RNAi and brain shuttle fields to create precision medicines for neurodegenerative diseases. The biotech, named Aerska, launched Wednesday...
View ArticleVertanical unpacks Phase 3 success for cannabis-based painkiller
Vertanical has shared positive results from its only asset in a late-stage trial of 820 people with chronic lower back pain as it awaits the outcome of a review in certain European countries. On...
View ArticleAnsa Biotechnologies closes $54.4M Series B to boost US DNA manufacturingÂ
California-based synthetic DNA maker Ansa Biotechnologies has closed an oversubscribed Series B funding round with $45.2 million, plus commitments for an additional $9.2 million. The cash will be used...
View ArticleFDA rejects treatment for rare copper deficiency over manufacturing
The FDA has rejected a copper replacement therapy for a rare and fatal genetic condition called Menkes disease, Fortress Biotech and its subsidiary Cyprium Therapeutics announced Wednesday morning....
View ArticlePost-Hoc Live: Unpacking Trump and Pfizerâs 'most favored nation' deal
After months of negotiations and anticipation, the Trump administration finally rolled out the first of its deals with drugmakers under its âmost favored nationâ policy. Weâve been tracking talks...
View ArticleEnanta aims to raise $50M as it advances RSV therapy; Hinge, Kyorin make a deal
Plus, news about Palisade Bio, Betta Pharmaceuticals, Binhui Biopharmaceutical, Appili Therapeutics, Vitalex Biosciences, Alpha Cognition, Klotho Neurosciences and Turn Biotechnologies: đ° Enanta seeks...
View ArticleHalozyme to spend $750M upfront to buy Elektrofi, a biologics tech delivery...
Halozyme Therapeutics is buying a peer in drug delivery technology with a $750 million deal for privately-held Elektrofi, the companies said Wednesday morning. Halozyme has built up a broad suite of ...
View ArticleTakeda stops all work in cell therapyÂ
Takeda is discontinuing its cell therapy efforts after it already pared back its work in the field. Itâs another blow to a cell therapy industry that has fallen out of favor as companies struggled to ...
View ArticleExclusive: French startup's gene therapy dramatically reduces urinary...
A Paris-based biotech startup unveiled the first results for its gene therapy designed to reduce uncontrolled urination in people with spinal cord injury. In an exclusive interview with Endpoints News,...
View ArticleTrumpâs 100% pharma tariff wonât start Oct. 1, White House confirms
The Trump administration is starting to prepare tariffs on some pharma companies, but those levies wonât take effect on Wednesday, a White House official confirmed to Endpoints News. President Donald...
View ArticleBiogen owes Genentech $88M in royalties from Tysabri, court rules
Biogen should pay Genentech more than $88 million in additional royalties for using Genentechâs patented process to help make the monoclonal antibody Tysabri, a California federal judge ruled. The case...
View ArticlePfizer-White House deal prompts pharma rally on Wall Street
Of all the obstacles that the pharmaceutical industry has faced in the first year of President Donald Trumpâs second term, none have struck more fear in executives, board rooms and investors than the...
View ArticleThird-round IRA guidance spells out new orphan drug protections
CMS finalized guidance this week that the agency says will increase transparency in the third round of Medicare drug price negotiations and âpreserve critical incentives for rare disease research.â The...
View ArticleExclusive: Upcoming ACIP meeting may move to December
The CDC is considering rescheduling the next meeting of the Advisory Committee on Immunization Practices for December, an administration official told Endpoints News. The official, granted anonymity to...
View Article